Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions

References

• Chintakuntlawar AV, Chodosh J. Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis. Ocul Immunol Inflamm. 2010;18(5):341–345. doi:10.3109/09273948.2010.498658
   PubMed Web of Science ®Google Scholar
• Chigbu DI, Labib BA. Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist. 2018;11:981–993. doi:10.2147/IDR.S162669
   PubMed Web of Science ®Google Scholar
• Radke JR, Cook JL. Human adenovirus infections: update and consideration of mechanisms of viral persistence. Curr Opin Infect Dis. 2018;31(3):251–256. doi:10.1097/QCO.0000000000000451
   Web of Science ®Google Scholar
• Iacobelli-Martinez M, Nemerow GR. Preferential activation of toll-like receptor nine by CD46-utilizing adenoviruses. J Virol. 2007;81(3):1305–1312. doi:10.1128/JVI.01926-06
   Web of Science ®Google Scholar
• Iacobelli-martinez M, Nepomuceno RR, Connolly J, Nemerow GR. CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines. J Virol. 2005;79(17):11259–11268. doi:10.1128/JVI.79.17.11259-11268.2005
   Web of Science ®Google Scholar
• Chen RF, Lee CY. Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection. Int Rev Immunol. 2014;33(1):45–53. doi:10.3109/08830185.2013.823420
   PubMed Web of Science ®Google Scholar
• Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. Innate immunity to adenovirus. Hum Gene Ther. 2014;25(4):265–284. doi:10.1089/hum.2014.001
   PubMed Web of Science ®Google Scholar
• Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology. 2009;384(2):380–388. doi:10.1016/j.virol.2008.10.016
   PubMed Web of Science ®Google Scholar
• Smith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol. 2010;343:195–224. doi:10.1007/82_2010_16
   PubMed Web of Science ®Google Scholar
• Gordon YJ, Araullo-Cruz TP, Johnson YF, Romanowski EG, Kinchington PR. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Invest Ophthalmol Vis Sci. 1996;37(13):2774–2778.
   PubMed Web of Science ®Google Scholar
• Kosulin K. Intestinal HAdV infection: tissue specificity, persistence, and implications for antiviral therapy. Viruses. 2019;11:9. doi:10.3390/v11090804
   Web of Science ®Google Scholar
• Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014;4(1):26–33. doi:10.1556/EuJMI.4.2014.1.2
   PubMedGoogle Scholar
• Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441–462. doi:10.1128/CMR.00116-13
   PubMed Web of Science ®Google Scholar
• Kalu SU, Loeffelholz M, Beck E, et al. Persistence of adenovirus nucleic acids in nasopharyngeal secretions: a diagnostic conundrum. Pediatr Infect Dis J. 2010;29(8):746–750. doi:10.1097/INF.0b013e3181d743c8
   Web of Science ®Google Scholar
• Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol. 2010;30(19):4564–4574. doi:10.1128/MCB.00146-10
   PubMed Web of Science ®Google Scholar
• Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol. 2003;170(9):4833–4839. doi:10.4049/jimmunol.170.9.4833
   PubMed Web of Science ®Google Scholar
• Garnett CT, Talekar G, Mahr JA, et al. Latent species C adenoviruses in human tonsil tissues. J Virol. 2009;83(6):2417–2428. doi:10.1128/JVI.02392-08
   PubMed Web of Science ®Google Scholar
• Kosulin K, Geiger E, Vecsei A, et al. Persistence and reactivation of human adenoviruses in the gastrointestinal tract. Clin Microbiol Infect. 2016;22(4):381 e381–381 e388. doi:10.1016/j.cmi.2015.12.013
   Web of Science ®Google Scholar
• Lion T. Adenovirus persistence, reactivation, and clinical management. FEBS Lett. 2019;593:3571–3582. doi:10.1002/1873-3468.13576
   Web of Science ®Google Scholar
• Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol. 2002;76(21):10608–10616. doi:10.1128/JVI.76.21.10608-10616.2002
   PubMed Web of Science ®Google Scholar
• Kosulin K, Pichler H, Lawitschka A, Geyeregger R, Lion T. Diagnostic parameters of adenoviremia in pediatric stem cell transplant recipients. Front Microbiol. 2019;10:414. doi:10.3389/fmicb.2019.00414
   PubMed Web of Science ®Google Scholar
• Avolio M, De Rosa R, Modolo ML, Stano P, Camporese A. When should adenoviral non-gonococcal urethritis be suspected? Two case reports. New Microbiol. 2014;37(1):109–112.
   Web of Science ®Google Scholar
• Liddle OL, Samuel MI, Sudhanva M, Ellis J, Taylor C. Adenovirus urethritis and concurrent conjunctivitis: a case series and review of the literature. Sex Transm Infect. 2015;91(2):87–90. doi:10.1136/sextrans-2014-051868
   Web of Science ®Google Scholar
• Samaraweera GR, Garcia K, Druce J, et al. Characteristics of adenovirus urethritis among heterosexual men and men who have sex with men: a review of clinical cases. Sex Transm Infect. 2016;92(3):172–174. doi:10.1136/sextrans-2015-052243
   Web of Science ®Google Scholar
• Tabrizi SN, Ling AE, Bradshaw CS, Fairley CK, Garland SM. Human adenoviruses types associated with non-gonococcal urethritis. Sex Health. 2007;4(1):41–44. doi:10.1071/SH06054
   Web of Science ®Google Scholar
• de Jong JC, Wigand R, Wadell G, et al. Adenovirus 37: identification and characterization of a medically important new adenovirus type of subgroup D. J Med Virol. 1981;7(2):105–118. doi:10.1002/jmv.1890070204
   Web of Science ®Google Scholar
• Sun G, Su G, Bai Y, Yang H. Analysis on the treatment and prevention of epidemic conjunctivitis in 108 cases. Pak J Pharm Sci. 2017;30(4(Suppl.)):1501–1503.
   Web of Science ®Google Scholar
• Buehler JW, Finton RJ, Goodman RA, et al. Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention. Infect Control. 1984;5(8):390–394. doi:10.1017/S0195941700062238
   Google Scholar
• Omar Akhtar A, Singh H, Si F, Hodge WG. A systematic review and cost-effectiveness analysis of tonometer disinfection methods. Can J Ophthalmol. 2014;49(4):345–350. doi:10.1016/j.jcjo.2014.04.003
   Web of Science ®Google Scholar
• Vermeulen H, Westerbos SJ, Ubbink DT. Benefit and harm of iodine in wound care: a systematic review. J Hosp Infect. 2010;76(3):191–199. doi:10.1016/j.jhin.2010.04.026
   Web of Science ®Google Scholar
• Reimer K, Wichelhaus TA, Schafer V, et al. Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology. 2002;204(Suppl 1):114–120. doi:10.1159/000057738
   Web of Science ®Google Scholar
• Bigliardi PL, Alsagoff SAL, El-kafrawi HY, Pyon JK, Wa CTC, Villa MA. Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg. 2017;44:260–268. doi:10.1016/j.ijsu.2017.06.073
   PubMed Web of Science ®Google Scholar
• Beukelman CJ, van den Berg AJ, Hoekstra MJ, Uhl R, Reimer K, Mueller S. Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns. 2008;34(6):845–855. doi:10.1016/j.burns.2007.11.014
   PubMed Web of Science ®Google Scholar
• Yazar H, Yarbag A, Balci M, Teker B, Tanyeri P. The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis. J Pak Med Assoc. 2016;66(8):968–970.
   Web of Science ®Google Scholar
• Sauerbrei A, Wutzler P. Virucidal efficacy of povidone-iodine-containing disinfectants. Lett Appl Microbiol. 2010;51(2):158–163. doi:10.1111/j.1472-765X.2010.02871.x
   PubMed Web of Science ®Google Scholar
• Yates KA, Shanks RMQ, Kowalski RP, Romanowski EG. The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types. J Ocul Pharmacol Ther. 2019;35(2):132–136. doi:10.1089/jop.2018.0122
   PubMed Web of Science ®Google Scholar
• Cheung D, Bremner J, Chan JT. Epidemic kerato-conjunctivitis–do outbreaks have to be epidemic? Eye (Lond). 2003;17(3):356–363. doi:10.1038/sj.eye.6700330
   Web of Science ®Google Scholar
• Dart JK, El-amir AN, Maddison T, et al. Identification and control of nosocomial adenovirus keratoconjunctivitis in an ophthalmic department. Br J Ophthalmol. 2009;93(1):18–20. doi:10.1136/bjo.2007.130112
   Web of Science ®Google Scholar
• Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect Dis Ther. 2015;4(4):491–501. doi:10.1007/s40121-015-0091-9
   PubMed Web of Science ®Google Scholar
• Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002;134(5):681–688. doi:10.1016/S0002-9394(02)01701-4
   PubMed Web of Science ®Google Scholar
• Pham TT, Burchette JL Jr., Hale LP. Fatal disseminated adenovirus infections in immunocompromised patients. Am J Clin Pathol. 2003;120(4):575–583. doi:10.1309/AWXDGNC5D70EN7YT
   Web of Science ®Google Scholar
• Kim SJ, Kim K, Park SB, Hong DJ, Jhun BW. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One. 2015;10(4):e0122642. doi:10.1371/journal.pone.0122642
   PubMed Web of Science ®Google Scholar
• Ying B, Tollefson AE, Spencer JF, et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother. 2014;58(12):7171–7181. doi:10.1128/AAC.03860-14
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. New drug on the horizon for treating adenovirus. Expert Opin Pharmacother. 2015;16(14):2095–2099. doi:10.1517/14656566.2015.1083975
   PubMed Web of Science ®Google Scholar
• Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341–352. doi:10.1016/S1083-8791(03)00102-2
   PubMed Web of Science ®Google Scholar
• Huang J, Kadonosono K, Uchio E. Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods. Clin Ophthalmol. 2014;8:315–320. doi:10.2147/OPTH.S55284
   PubMedGoogle Scholar
• Toth K, Ying B, Tollefson AE, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses. 2015;7(3):1409–1428. doi:10.3390/v7031409
   PubMed Web of Science ®Google Scholar
• de Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res. 1996;31(3):165–172. doi:10.1016/0166-3542(95)00962-0
   Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001;52(3):275–280. doi:10.1016/S0166-3542(01)00166-8
   PubMed Web of Science ®Google Scholar
• Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci. 1994;35(12):4135–4143.
   PubMed Web of Science ®Google Scholar
• Inoue H, Sonoda KH, Ishikawa M, Kadonosono K, Uchio E. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo. Ophthalmologica. 2009;223(4):233–238. doi:10.1159/000205585
   Web of Science ®Google Scholar
• Clement C, Capriotti JA, Kumar M, et al. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2011;52(1):339–344. doi:10.1167/iovs.10-5944
   PubMed Web of Science ®Google Scholar
• Kinchington PR, Araullo-Cruz T, Vergnes JP, Yates K, Gordon YJ. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antiviral Res. 2002;56(1):73–84. doi:10.1016/S0166-3542(02)00098-0
   Web of Science ®Google Scholar
• Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42(8):1812–1815.
   PubMed Web of Science ®Google Scholar
• Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant. 2017;23(3):512–521. doi:10.1016/j.bbmt.2016.12.621
   PubMed Web of Science ®Google Scholar
• Averbuch D, Safadi R, Dar D, et al. Successful brincidofovir treatment of metagenomics-detected adenovirus infection in a severely ill signal transducer and activator of transcription-1-deficient patient. Pediatr Infect Dis J. 2019;38(3):297–299. doi:10.1097/INF.0000000000002090
   Web of Science ®Google Scholar
• 2017 American transplant congress abstracts. Am J Transplant. 2017;17(Suppl 3):5–815.
   Google Scholar
• Goossens PH, Vogels R, Pieterman E, et al. The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum. 2001;44(1):48–52. doi:10.1002/1529-0131(200101)44:1<48::AID-ANR7>3.0.CO;2-D
   Web of Science ®Google Scholar
• Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci. 2007;48(9):4171–4176. doi:10.1167/iovs.07-0491
   PubMed Web of Science ®Google Scholar
• Martin T, Duffy SF, Carson DA, Kipps TJ. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992;175(4):983–991. doi:10.1084/jem.175.4.983
   PubMed Web of Science ®Google Scholar
• Ozturk HE, Sonmez B, Beden U. Corneal sensitivity may decrease in adenoviral epidemic keratoconjunctivitis–a confocal microscopic study. Eye Contact Lens. 2013;39(4):264–268. doi:10.1097/ICL.0b013e31828ef19b
   Web of Science ®Google Scholar
• Meyer-rusenberg B, Loderstadt U, Richard G, Kaulfers PM, Gesser C. Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch Arztebl Int. 2011;108(27):475–480. doi:10.3238/arztebl.2011.0475
   PubMed Web of Science ®Google Scholar
• Kaufman HE. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res. 2000;19(1):69–85. doi:10.1016/S1350-9462(99)00004-X
   PubMed Web of Science ®Google Scholar
• Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002;109(5):845–850. doi:10.1016/S0161-6420(02)00992-2
   PubMed Web of Science ®Google Scholar
• Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol. 2001;119(10):1487–1491. doi:10.1001/archopht.119.10.1487
   Google Scholar
• Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638–640. doi:10.1097/ICO.0b013e3181c33034
   Web of Science ®Google Scholar
• Reinhard T, Godehardt E, Pfahl HG, Sundmacher R. [Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. A pilot study]. Ophthalmologe. 2000;97(11):764–768. German. doi:10.1007/s003470070025.
   Web of Science ®Google Scholar
• Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41(6):693–698. doi:10.3129/i06-061
   PubMed Web of Science ®Google Scholar
• Okumus S, Coskun E, Tatar MG, et al. Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol. 2012;12:42. doi:10.1186/1471-2415-12-42
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P. Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis. Indian J Ophthalmol. 2019;67(5):594–598. doi:10.4103/ijo.IJO_1352_18
   Web of Science ®Google Scholar
• Kocluk Y, Sukgen EA, Cevher S, Mat E. Symptomatic treatment of subepithelial infiltrates after viral conjunctivitis: loteprednol or dexamethasone? Ocul Immunol Inflamm. 2017;25(5):649–653. doi:10.3109/09273948.2016.1149593
   Web of Science ®Google Scholar
• Asena L, Singar Ozdemir E, Burcu A, Ercan E, Colak M, Altinors DD. Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis. Eye (Lond). 2017;31(5):781–787. doi:10.1038/eye.2017.4
   Web of Science ®Google Scholar
• Gordon YJ, Araullo-cruz T, Romanowski EG. The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol. 1998;116(7):900–905. doi:10.1001/archopht.116.7.900
   Google Scholar
• Kessel L, Tendal B, Jorgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014;121(10):1915–1924. doi:10.1016/j.ophtha.2014.04.035
   PubMed Web of Science ®Google Scholar
• Malik A, Sadafale A, Gupta YK, Gupta A. A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation. Oman J Ophthalmol. 2016;9(3):150–156. doi:10.4103/0974-620X.192268
   PubMedGoogle Scholar
• Dunn JP. Uveitis. Prim Care. 2015;42(3):305–323. doi:10.1016/j.pop.2015.05.003
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31(3):159–169. doi:10.1016/0039-6257(86)90035-4
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Pless P, Yates KA, Gordon YJ. Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea. 2005;24(1):86–91. doi:10.1097/01.ico.0000127481.23714.b6
   Web of Science ®Google Scholar
• Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109(5):610–612. doi:10.1016/S0002-9394(14)70704-4
   Web of Science ®Google Scholar
• Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12(5):413–419. doi:10.1097/00003226-199309000-00008
   PubMed Web of Science ®Google Scholar
• Perry HD, Doshi-carnevale S, Donnenfeld ED, Kornstein HS. Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology. 2003;110(8):1578–1581. doi:10.1016/S0161-6420(03)00538-4
   PubMed Web of Science ®Google Scholar
• Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. 1993;24(6):472–495. doi:10.2165/00003088-199324060-00004
   PubMed Web of Science ®Google Scholar
• Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–591. doi:10.1097/00007691-199512000-00007
   PubMed Web of Science ®Google Scholar
• Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db84
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190. doi:10.1038/nri3156
   PubMed Web of Science ®Google Scholar
• Almawi WY, Melemedjian OK. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant. 2000;15(12):1916–1918. doi:10.1093/ndt/15.12.1916
   Web of Science ®Google Scholar
• Ghanem RC, Vargas JF, Ghanem VC. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. Cornea. 2014;33(11):1210–1213. doi:10.1097/ICO.0000000000000247
   PubMed Web of Science ®Google Scholar
• Grosso F, Stoilov P, Lingwood C, Brown M, Cochrane A. Suppression of adenovirus replication by cardiotonic steroids. J Virol. 2017;91:3. doi:10.1128/JVI.01623-16
   Web of Science ®Google Scholar
• Hartley C, Hartley M, Pardoe I, Knight A. Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151(12):2495–2501. doi:10.1007/s00705-006-0824-x
   Web of Science ®Google Scholar
• Marrugal-lorenzo JA, Serna-gallego A, Gonzalez-gonzalez L, et al. Inhibition of adenovirus infection by mifepristone. Antiviral Res. 2018;159:77–83. doi:10.1016/j.antiviral.2018.09.011
   Web of Science ®Google Scholar
• Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009;26(8):776–783. doi:10.1007/s12325-009-0062-1
   PubMed Web of Science ®Google Scholar
• Kovalyuk N, Kaiserman I, Mimouni M, et al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Acta Ophthalmol. 2017;95(8):e686–e692. doi:10.1111/aos.13416
   PubMed Web of Science ®Google Scholar
• Pepose JS, Narvekar A, Liu W, Haque R. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol. 2019;13:535–544. doi:10.2147/OPTH.S191275
   Web of Science ®Google Scholar
• Pinto RD, Lira RP, Abe RY, et al. Dexamethasone/povidone eye drops versus artificial tears for treatment of presumed viral conjunctivitis: a randomized clinical trial. Curr Eye Res. 2015;40(9):870–877. doi:10.3109/02713683.2014.964419
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Yawata N, Aoki K, Kitaichi N. Challenges in management of epidemic keratoconjunctivitis with emerging recombinant human adenoviruses. J Clin Virol. 2019;112:1–9. doi:10.1016/j.jcv.2019.01.004
   Web of Science ®Google Scholar
• Yamazaki ES, Ferraz CA, Hazarbassanov RM, Allemann N, Campos M. Phototherapeutic keratectomy for the treatment of corneal opacities after epidemic keratoconjunctivitis. Am J Ophthalmol. 2011;151(1):35–43 e31. doi:10.1016/j.ajo.2010.07.028
   PubMed Web of Science ®Google Scholar
• Kepez Yildiz B, Urvasizoglu S, Yildirim Y, et al. Changes in higher-order aberrations after phototherapeutic keratectomy for subepithelial corneal infiltrates after epidemic keratoconjunctivitis. Cornea. 2017;36(10):1233–1236. doi:10.1097/ICO.0000000000001296
   PubMed Web of Science ®Google Scholar
• Subasi S, Yuksel N, Toprak M, Yilmaz Tugan B. In vivo confocal microscopy analysis of the corneal layers in adenoviral epidemic keratoconjunctivitis. Turk J Ophthalmol. 2018;48(6):276–280. doi:10.4274/tjo.59251
   Google Scholar
• Nilsson EC, Storm RJ, Bauer J, et al. The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. Nat Med. 2011;17(1):105–109. doi:10.1038/nm.2267
   PubMed Web of Science ®Google Scholar
• Bunz O, Mese K, Zhang W, Piwowarczyk A, Ehrhardt A, Hamblin MR. Effect of cold atmospheric plasma (CAP) on human adenoviruses is adenovirus type-dependent. PLoS One. 2018;13(10):e0202352. doi:10.1371/journal.pone.0202352
   Web of Science ®Google Scholar
• de Mercoyrol L, Corda Y, Job C, Job D. Accuracy of wheat-germ RNA polymerase II. General enzymatic properties and effect of template conformational transition from right-handed B-DNA to left-handed Z-DNA. Eur J Biochem. 1992;206(1):49–58. doi:10.1111/ejb.1992.206.issue-1
   Google Scholar
• Garcia-zalisnak D, Rapuano C, Sheppard JD, Davis AR. Adenovirus ocular infections: prevalence, pathology, pitfalls, and practical pointers. Eye Contact Lens. 2018;44(Suppl 1):S1–S7. doi:10.1097/ICL.0000000000000226
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Shanks RMQ, Kowalski RP. Benzalkonium chloride demonstrates concentration-dependent antiviral activity against adenovirus in vitro. J Ocul Pharmacol Ther. 2019;35(5):311–314. doi:10.1089/jop.2018.0145
   Web of Science ®Google Scholar
• Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343–346. doi:10.1080/15569527.2017.1291665
   PubMed Web of Science ®Google Scholar
• Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res. 2014;112:38–46. doi:10.1016/j.antiviral.2014.10.005
   PubMed Web of Science ®Google Scholar
• Gordon YJ, Naesens L, DeClercq E, Maudgal PC, Veckeneer M. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea. 1996;15(5):546. doi:10.1097/00003226-199609000-00018
   PubMed Web of Science ®Google Scholar
• Kinchington PR, Romanowski EG, Jerold Gordon Y. Prospects for adenovirus antivirals. J Antimicrob Chemother. 2005;55(4):424–429. doi:10.1093/jac/dki057
   PubMed Web of Science ®Google Scholar
• Yabiku ST, Yabiku MM, Bottos KM, Araujo AL, Freitas D, Belfort R Jr. [Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis]. Arq Bras Oftalmol. 2011;74(6):417–421. Portuguese. doi:10.1590/S0004-27492011000600007.
   PubMed Web of Science ®Google Scholar
• Ozen S, Ozer MA. Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection. Int Ophthalmol. 2017;37(1):245–249. doi:10.1007/s10792-016-0260-1
   Web of Science ®Google Scholar
• Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis. 2005;191(3):396–399. doi:10.1086/jid.2005.191.issue-3
   PubMed Web of Science ®Google Scholar
• Van Genechten T, van Heerden J, Bauters T, Dhooge C. Successful treatment of adenovirus infection with brincidofovir in an immunocompromised patient after hematological stem cell transplantation. Case Rep Infect Dis. 2020;2020:5981289.
   Web of Science ®Google Scholar
• Meena JP, Phillips RS, Kinsey S. Brincidofovir as a salvage therapy in controlling adenoviremia in pediatric recipients of hematopoietic stem cell transplant. J Pediatr Hematol Oncol. 2019;41(7):e467–e472. doi:10.1097/MPH.0000000000001480
   Web of Science ®Google Scholar
• Sulejmani N, Nagai S, Safwan M, et al. Brincidofovir as salvage therapy for adenovirus disease in intestinal transplant recipients. Pharmacotherapy. 2018;38(4):470–475. doi:10.1002/phar.2018.38.issue-4
   Web of Science ®Google Scholar
• Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res. 2017;143:269–277. doi:10.1016/j.antiviral.2017.01.009
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369–381. doi:10.1016/j.bbmt.2018.09.038
   PubMed Web of Science ®Google Scholar
• Daniel BS, Orchard D. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Australas J Dermatol. 2015;56(3):164–169. doi:10.1111/ajd.2015.56.issue-3
   Web of Science ®Google Scholar
• Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30(9):958–961. doi:10.1097/ICO.0b013e31820cd607
   Web of Science ®Google Scholar
• Muftuoglu IK, Akova YA, Gungor SG. Effect of 0.05% topical cyclosporine for the treatment of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis. Int J Ophthalmol. 2016;9(4):634–635. doi:10.18240/ijo.2016.04.26
   Web of Science ®Google Scholar
• Bayraktutar BN, Ucakhan OO. Comparison of efficacy of two different topical 0.05% cyclosporine a formulations in the treatment of adenoviral keratoconjunctivitis-related subepithelial infiltrates. Case Rep Ophthalmol. 2016;7(1):135–140. doi:10.1159/000444784
   Google Scholar
• Pucci N, Caputo R, Mori F, et al. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Int J Immunopathol Pharmacol. 2010;23(3):865–871. doi:10.1177/039463201002300322
   PubMed Web of Science ®Google Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37–42. doi:10.4137/OED.S16067
   PubMedGoogle Scholar
• Levinger E, Trivizki O, Shachar Y, Levinger S, Topical VD. 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(5):811–816. doi:10.1007/s00417-014-2611-9
   PubMed Web of Science ®Google Scholar
• Berisa Prado S, Riestra Ayora AC, Lisa Fernandez C, Chacon Rodriguez M, Merayo-lloves J, Alfonso Sanchez JF. Topical tacrolimus for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2017;36(9):1102–1105. doi:10.1097/ICO.0000000000001279
   Web of Science ®Google Scholar
• Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res. 2016;10(6):NC05–NC09. doi:10.7860/JCDR/2016/17847.7978
   Google Scholar